Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia

Resuscitation

Volumn 81, Issue 1, 2010, Pages 47-52

  Shiga, Tsuyoshi ^a   Tanaka, Keiji ^b   Kato, Rinya ^c   Amino, Mari ^d   Matsudo, Yuji ^e   Honda, Toshihiro ^f   Sagara, Koichi ^g   Takahashi, Atsushi ^a   Katoh, Takao ^b   Urashima, Mitsuyoshi ^h   Ogawa, Satoshi ⁱ   Takano, Teruo ^b   Kasanuki, Hiroshi ^j  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c Nagoya Ekisaikai Hospital   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KIMITSU CHUO HOSPITAL   (Japan)

^f Saisei kai Kumamoto Hospital   (Japan)

^g THE CARDIOVASCULAR INSTITUTE   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ International University of Health and Welfare Mita Hospital   (Japan)

^j WASEDA UNIVERSITY   (Japan)

more..

Author keywords

Anti arrhythmic drug; Defibrillation; Lidocaine; Nifekalant; Ventricular fibrillation

Indexed keywords

LIDOCAINE; NIFEKALANT;

ADULT; ARTICLE; ASYSTOLE; CIRCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PULSELESS ELECTRICAL ACTIVITY; QT PROLONGATION; RISK FACTOR; SHOCK; SINGLE DRUG DOSE; SURVIVAL RATE; THERAPY RESISTANCE; TORSADE DES POINTES; TREATMENT DURATION;

AGED; ANTI-ARRHYTHMIA AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 72049098182     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2009.09.027     Document Type: Article

References (25)

1. 2005 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 7.2. Management of cardiac arrest. Circulation 112 (2005) IV-58-IV-66
2. Kudenchuk P.J., Cobb L.A., Copass M.K., et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341 (1999) 871-878
3. Dorian P., Cass D., Schwartz B., Cooper R., Gelaznikas R., and Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346 (2002) 884-890
4. Nakaya H., Tohse N., Takeda Y., and Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 109 (1993) 157-163
5. Kamiya J., Ishii M., and Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 58 (1992) 107-115
6. Isomoto S., Konoe A., Centurión O.A., et al. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. Pacing Clin Electrophysiol 18 (1995) 2022-2027
7. Onishi S., Kasanuki H., Shoda M., et al. Efficacy of intravenous doses of MS-551 for drug-resistant sustained ventricular tachycardia. J Clin Ther Med 13 (1997) 1759-1771 [in Japanese, English abstract]
8. Shiga T., Shoda M., Matsuda N., et al. Electrophysiological characteristic of a patient exhibiting the short-coupled variant of torsade de pointes. J Electrocardiol 34 (2001) 271-275
9. Katoh T., Mitamura H., Matsuda N., Takano T., Ogawa S., and Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias. Post-marketing special investigation. Circ J 69 (2005) 1237-1243
10. Amino M., Yoshioka K., Iwata O., et al. Efficacy of nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest. J Cardiol 41 (2003) 127-134 [in Japanese, English abstract]
11. Shimizu K., Sugita M., Kuroki T., et al. The effectiveness of nifekalant for out-of-hospital cardiopulmonary arrest with intractable ventricular fibrillation. J Jpn Soc Intensive Care Med 11 (2004) 105-110 [in Japanese, English abstract]
12. Igarashi M., Fujino T., Toyoda M., et al. Defibrillation effects of nifekalant in patients with out-of-hospital ventricular fibrillation. Pacing Clin Electrophysiol 28 (2005) S155-S157
13. Yoshioka K., Amino M., Morita S., et al. Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? Comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis. Circ J 70 (2006) 21-27
14. Tahara Y., Kimura K., Kosuge M., et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J 70 (2006) 442-446
15. Kovoor P., Love A., Hall J., et al. Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. Intern Med J 35 (2005) 518-525
16. Katoh T., Tsunoo M., Mitsuhashi T., et al. Phase I study of MS-551 (I): a single intravenous injection study. J Clin Ther Med 13 (1997) 1659-1674 [in Japanese, English abstract]
17. Mounsey J.P., and DiMarco J.P. Cardiovascular drugs. Dofetilide. Circulation 102 (2000) 2665-2670
18. Kerber R.E., Pandian N.G., Jensen S.R., et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol 7 (1986) 397-405
19. Dopp A.L., Miller J.M., and Tisdale J.E. Effect of drugs on defibrillation capacity. Drugs 68 (2008) 607-630
20. Zhou L., Chen B.P., Kluger J., Fan C., and Chow M.S.S. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 31 (1998) 1672-1678
21. Murakawa Y., Yamashita T., Kanese Y., and Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?. J Am Coll Cardiol 29 (1997) 688-692
22. Simon R.D., Sturdivant J.L., Leman R.B., Wharton J.M., and Gold M.R. The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol 32 (2009) 24-28
23. Zhong J.Q., and Dorian P. Epinephrine and vasopressin during cardiopulmonary resuscitation. Resuscitation 66 (2005) 263-269
24. Weaver W.D., Fahrenbruch C.E., Johnson D.D., Hallstrom A.P., Cobb L.A., and Copass M.K. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation 82 (1990) 2027-2034
25. van Walraven C., Stiell I.G., Wells G.A., Hébert P.C., and Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC study group. Ann Emerg Med 32 (1998) 544-553